Antibe Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing safer and more effective therapies for pain and inflammation. Leveraging its proprietary hydrogen sulfide (H₂S)–releasing drug platform, Antibe aims to overcome the gastrointestinal and cardiovascular risks commonly associated with nonsteroidal anti-inflammatory drugs (NSAIDs). The company’s lead candidate, otenaproxesul (formerly ATB-346), is a novel derivative of naproxen designed to provide potent analgesic and anti-inflammatory effects while reducing the incidence of gastrointestinal ulceration.
Since its founding in 2009, Antibe has advanced otenaproxesul through multiple clinical trials, with a pivotal Phase III program targeting osteoarthritis pain. In parallel, the company is developing additional H₂S-releasing molecules, including ATB-353 and ATB-352, to address various pain indications and inflammatory disorders. Antibe’s research collaborations with leading academic institutions have contributed to a robust preclinical pipeline and validated the therapeutic potential of its drug delivery platform.
Headquartered in Toronto, Canada, Antibe Therapeutics maintains a global development footprint with regulatory and clinical operations spanning North America and Europe. The company has established strategic partnerships to facilitate Phase III studies in key markets and to prepare for potential commercialization. Antibe continues to engage with regulatory authorities on both sides of the Atlantic to ensure streamlined access to its breakthrough therapies.
Under the leadership of Chief Executive Officer Steve Watt and Chief Scientific Officer John Wallace, Antibe has built a management team with extensive experience in drug development, regulatory affairs, and commercialization. The board of directors and senior advisors bring deep expertise in pharmaceutical innovation and business strategy, positioning Antibe to advance its pipeline toward registration and market launch.
AI Generated. May Contain Errors.
